Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.32 |
| ▸ | POLRMT | O00411 | 1/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18636621 | 0.99 | CYP3A4 (0.38) | CYP3A4CYP2C9RIPK1POLRMTBTN3A1 | |
| SCHEMBL18636469 | 0.99 | CYP3A4 (0.38) | CYP3A4CYP2C9RIPK1POLRMTBTN3A1 | |
| SCHEMBL18636489 | 0.98 | CYP3A4 (0.38) | CYP3A4CYP2C9RIPK1POLRMTBTN3A1 | |
| SCHEMBL24149257 | 0.93 | CYP3A4 (0.33) | CYP3A4CYP2C9POLRMT | |
| SCHEMBL24149199 | 0.92 | DOT1L (0.33) | CYP3A4CYP2C9POLRMT | |
| SCHEMBL25013577 | 0.92 | CYP3A4 (0.32) | CYP3A4CYP2C9POLRMT | |
| SCHEMBL25012732 | 0.92 | CYP3A4 (0.38) | CYP3A4CYP2C9RIPK1BTN3A1 | |
| SCHEMBL20078684 | 0.91 | CYP3A4 (0.41) | CYP3A4CYP2C9RIPK1POLRMTBTN3A1 | |
| SCHEMBL18636597 | 0.91 | CYP3A4 (0.41) | CYP3A4CYP2C9RIPK1POLRMTBTN3A1 | |
| SCHEMBL18636485 | 0.91 | CYP3A4 (0.40) | CYP3A4CYP2C9RIPK1BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11344565-B2 | Methods for the preparation of ribosides | GILEAD SCIENCES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210393659-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2021-12-23 | — | — | US | disclosed |
| EP-3212175-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20210283150-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| US-11007208-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3785717-A1 | METHODS FOR TREATING CORONAVIRIDAE INFECTIONS | Gilead Sciences, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20200352967-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2020-11-12 | — | — | US | disclosed |
| EP-3695844-A1 | METHODS FOR TREATING NIPAH VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10695357-B2 | Methods for treating filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10695361-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190275063-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-09-12 | — | — | US | disclosed |
| US-20190255085-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-08-22 | — | — | US | disclosed |
| US-10251904-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10251898-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9724360-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| WO-2017049060-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251904-B2 | Methods for treating arenaviridae and coronaviridae virus infections | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885RIPK1 902/4885 |
| US-20190275063-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | CYP3A4 772/4885CYP2C9 2974/4885RIPK1 2292/4885 |
| US-10695361-B2 | Methods for treating arenaviridae and coronaviridae virus infections | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885RIPK1 902/4885 |
| US-11007208-B2 | Methods for treating arenaviridae and coronaviridae virus infections | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885RIPK1 902/4885 |
| US-11344565-B2 | Methods for the preparation of ribosides | RUVBL2, RUVBL1, EIF2AK2 | CYP3A4 2996/4885CYP2C9 4188/4885RIPK1 686/4885 |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885RIPK1 902/4885 |
| US-20190255085-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885RIPK1 902/4885 |
| US-20210393659-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885RIPK1 902/4885 |
| US-10695357-B2 | Methods for treating filoviridae virus infections | PNP, PRPF4, RPIA | CYP3A4 772/4885CYP2C9 2974/4885RIPK1 2292/4885 |
| US-10251898-B2 | Methods for treating Filoviridae virus infections | PNP, PRPF4, RPIA | CYP3A4 772/4885CYP2C9 2974/4885RIPK1 2292/4885 |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885RIPK1 902/4885 |
| US-20200352967-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885RIPK1 902/4885 |
| US-20210283150-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | ACE2, ACE, PNP | CYP3A4 296/4885CYP2C9 476/4885RIPK1 2922/4885 |
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | PNP, ACE, ACE2 | CYP3A4 1181/4885CYP2C9 2188/4885RIPK1 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.